25 abril 2016

Sylentis ( Grupo PharmaMar ) . Posters que Presentara en el Congreso ARVO 2016 ( Seattle del 1 al 5 Mayo 2016 ) . Dos Farmacos ( Bamosiran y SYL1001 ) que sin apenas hacer ruido estan ante el posible inicio de la Fase III .

Resultado de imagen de sylentis logo



These are the posters that Sylentis will present at ARVO-2016.  1-5 MAY SEATTLE .




1*.- Presentation Number - Posterboard Number: 3040 - A0389

Abstract/Presentation Title: Stability study of Bamosiran (a siRNA compound) in ophthalmic solution in different containers .

Session Number: 314 
Session 
Title: Glaucoma Clinical studies / Pharmacology Session Date/ 
Times: May 3, 2016 from 8:30 AM to 10:15 AM

***************************************

2*.-  Presentation Number - Posterboard Number: 3023 - A0372

Abstract/Presentation Title: Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma .

Session Number: 314 
Session Title: Glaucoma Clinical studies / Pharmacology 
Session Date/ Times: May 3, 2016 from 8:30 AM to 10:15 AM.

***************************************

3*.-  Presentation Number - Posterboard Number: 2878 - A0087

Abstract/Presentation Title: Results of clinical trials with a novel RNA-based therapy (SYL1001) to treat patients with ocular pain associated to dry eye disease.

Session Number: 310 
Session Title: Dry Eye II 
Session Date/ Times: May 3, 2016 from 8:30 AM to 10:15 AM

Resultado de imagen de sylentis logo